Carregant...
Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
Brentuximab vedotin (BV) is an effective and well-tolerated treatment for patients with classical Hodgkin lymphoma (HL). It was initially approved by the US FDA for the treatment of HL after failure of autologous hematopoietic stem cell transplant (autoHSCT) or after failure of at least two prior li...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6130098/ https://ncbi.nlm.nih.gov/pubmed/30210755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620718786833 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|